Spotting and bleeding are among the most common side effects associated with oral
contraceptive (OC) use and their occurrence is a prime determinant of whether a new user …

Two triphasic oral contraceptives containing gestodene (GES)(a new progestogen) and
levonorgestrel (LNG) were compared with respect to contraceptive effect, cycle control …

OBJECTIVE: To assess the bleeding profile, acceptance and safety of an extended 126-day
regimen of the oral contraceptive Yasmin®[30 μg ethinylestradiol (EE) and 3 mg …

An open comparison at a single center was performed in volunteers (n= 58) randomly
allocated to two treatment groups, one receiving tablets containing 20 μg ethinylestradiol …

Objective In women who use oral contraceptives with low estrogen doses, a quiescent
endometrium is frequently produced. Further reduction of the estrogen dose would not be …

A triphasic, combined oral contraceptive containing 30—40—30 μg ethinyloestradiol (EE),
and 50—75—125 μg levonorgestrel was compared with a fixed dose combination …

The study reported herein is the primary efficacy and safety study conducted to support US
registration of an oral contraceptive containing 150 μg desogestrel and 30 μg ethinyl …

Long-cycle regimens with continuous use of oral contraceptives (OCs) for 3 or 6 months
followed by a hormone-free interval of 7 days may reduce or prevent cycle-dependent and …

The clinical and metabolic effects of a low-dose triphasic oral contraceptive containing
gestodene were investigated in 42 healthy women during 6 months of treatment. No …

Objective The aim of this study is to compare the effect of ethinyl estradiol 0.03
mg/gestodene 0.075 mg (EE/GSD) with ethinylestradiol 0.03 mg/drospirenone 3 mg …